Details for Patent: 9,089,571
✉ Email this page to a colleague
Title: | Quinazoline derivatives for the treatment of cancer diseases |
Abstract: | The present invention relates to the use of quinazolines of formula (I), ##STR00001## wherein the groups R.sup.a to R.sup.d have the meanings given in the claims and specification, in cancer therapy. |
Inventor(s): | Solca; Flavio (Vienna, AT), Amelsberg; Andree (Southbury, CT), van Meel; Jacobus C. A. (Moedling, AT), Baum; Anke (Hinterbruehl, AT), Stehle; Gerd (Ehingen, DE) |
Assignee: | Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) |
Filing Date: | Feb 14, 2013 |
Application Number: | 13/766,914 |
Claims: | 1. A method for treating head and neck squamous cell carcinoma in a patient, the method comprising administering a therapeutically effective amount of an EGFR inhibitor to the patient wherein said inhibitor is the compound 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-o- xo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline ##STR00012## or a physiologically acceptable salt thereof. 2. The method according to claim 1, wherein the Head and neck squamous cell carcinoma is selected from the group consisting of lip and oral cavity cancer, laryngeal cancer, nasopharyngeal cancer, oropharyngeal cancer and hypopharyngeal cancer. 3. The method according to claim 1 or 2, wherein the compound is (d') 4-[3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten- -1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline dimaleate. |